Micropulse laser trabeculoplasty on Chinese patients with glaucoma or ocular hypertension: average 35 months follow-up results

Yuting Yang1,2†, Xinting Huang1†, Sheng Liao1, Feng Zhang3, Jingming Shi1, Xuanchu Duan4 and Ke Liu1*

Abstract

Background: Glaucoma is a group of eye diseases that can damage the optic nerve and cause vision loss. A novel technology micropulse laser trabeculoplasty (MLT) can use duty-circle subvisible laser pulses to treat glaucoma. The aim of this study is to evaluate the efficacy of 360° MLT to alleviate intraocular pressure (IOP) in patients with glaucoma.

Methods: This was a single-center prospective study on patients treated with 360° MLT using a Diode True-Yellow 577-nm Laser with MicroPulse technology. All the patients were recruited from the Department of Ophthalmology. Follow-up visits were carried out at 1 day, 1 week, 1 month, 3 months, 6 months, 18 months, and 36 months after the procedure. Best-corrected visual acuity (BCVA), Intraocular pressure (IOP), and vertical cup-to-disc ratio (C/D ratio) were measured during the follow-up. Repeated-measures analysis of variance (ANOVA) and Kaplan–Meier analysis were performed to evaluate the outcomes.

Results: A total of 39 eyes from 25 patients were included in this study (10 men/15 women). The average age of patients was 41.47 ± 14.39 years old, and the baseline IOP was 21.13 ± 7.75 mmHg. MLT significantly reduced the IOP at 1 day (range 15.61–19.01, P = 0.0218), 3 months (range 16.47–19.22, P = 0.0390), and 6 months (range 15.38–18.56, P = 0.0332) compared with the baseline. However, by the end of the study, only 21.88% of patients demonstrated a ≥ 20% IOP reduction, while seven eyes needed further laser or surgical treatment. The IOP of glaucoma patients was significantly lower than the ocular hypertension patients at 1 month (P = 0.0124), 3 months (P = 0.0004), 18 months (P = 0.0061) and 36 months (P = 0.0119).

Conclusions: Micropulse laser trabeculoplasty reduce IOP in patients with glaucoma or ocular hypertension for a short period, but its lowering efficiency is limited up to 6 months of the follow-up period.

Keywords: Micropulse laser trabeculoplasty, Glaucoma, Ocular hypertension, Laser technology
180°-360° range of TM for each treatment [2, 3]. Micro-pulse laser trabeculoplasty (MLT) is a newly developed technology, first described in 2005. It uses duty-circle subvisible laser pulses and focuses on the anterior TM tissue. Considering its long relaxation time, micropulse laser trabeculoplasty allows the temperature to return to the baseline and avoids heat damage to TM [2]. Several clinical trials have been carried out to evaluate the efficacy and safety of MLT. However, the standard protocol for MLT was still not available, and studies continued to explore it [4–8]. Besides, even though some papers evaluated MLT’s efficacy, there’s still no data showed how long the IOP-reduction effect could last [9]. This study aimed to illustrate the effects of 360° MLT’s on Chinese patients with glaucoma or ocular hypertension within a longer follow-up period.

Methods
This was a prospective study conducted at the Second Xiangya Hospital from 2015 to 2019. All the patients were recruited from the Department of Ophthalmology.

The inclusion criteria were as follows: (1) patients of Asian origin with glaucoma or ocular hypertension (OHT); (2) age older than 18 years. The exclusion criteria were as follows: (1) received glaucoma surgery within 3 months; (2) history of trauma; (3) subjects who were unable to be followed-up. Slit-lamp examination and gonioscopy were performed, IOP was measured using Goldmann applanation, and visual field (VF) was also tested using the Humphrey Field Analyzer perimeter. Open-angle glaucoma (OAG) was defined as the open angle on gonioscopy (Shaffer grading > 2 in all quadrants) in the presence of a progressive increase in C/D ratio or VF defects. Patients with higher IOP, typically 21 mm Hg, but no VF or retinal nerve fibre layer (RNFL) defects were classified as OHT [10]. Two eyes diagnosed with primary angle-closure glaucoma were included after LPI treatment, with Shaffer grading ≥ 2 in all quadrants. Four eyes received filtering surgery before but IOP was not well controlled were also included. The patients were explained about the choices they had and the possibilities of adding other treatments. Informed consents were obtained from all participants.

Prior to MLT, topical anaesthesia (proparacaine hydrochloride 0.5%) was applied to the treated eye 5 min apart. All patients received a single session of MLT by the same surgeon using a Diode True-Yellow 577-nm Laser with MicroPulse technology (IQ 577 TM Laser System, Iridex Corporation, 1212 Terra Bella Avenue, Mountain View, CA, USA).

Patients went home immediately after the procedure. Nonsteroidal anti-inflammatory drugs (Pranoprofen, 0.1%) was applied four times a day for 1 week. BCVA and

| Table 1  Patient Demographics |
|-----------------------------|
| Baseline characteristics    | N = 39 |
| Laterality (right/ left)    | 24/15 |
| Gender (men/ women)         | 10/15 |
| Age (years) (mean ± SD)     | 41.47 ± 14.39 |
| Type of glaucoma            |       |
| Ocular hypertension         | 15    |
| POAG                        | 15    |
| PACG                        | 2     |
| Glaucomatocyclic crisis     | 2     |
| Corticosteroid glaucoma     | 2     |
| Glaucoma after silicone oil removal | 1 |
| Juvenile glaucoma           | 2     |
| Number of medications       |       |
| 0                           | 17    |
| 1                           | 14    |
| 2                           | 7     |
| > 2                         | 1     |
| Type of anti-glaucoma medications |       |
| Beta-blocker                | 11    |
| Prostaglandin agonists      | 9     |
| Carbonic anhydrase inhibitor| 4     |
| Alpha agonist               | 8     |
| Surgery before MLT          |       |
| LASIK                       | 3     |
| LPI                         | 2     |
| Silicone oil tamponade and removal | 1 |
| Scleral buckle              | 1     |
| Trabeculectomy              | 2     |
| Ex-PRESS shunt surgery      | 2     |
| Mean C/D ratio (mean ± SD)  | 0.63 ± 0.22 |
| Visual Field                |       |
| Visual field index (%) (mean ± SD) | 84 ± 25 |
| Mean deviation (dB) (mean ± SD) | -5.44 ± 6.69 |
| Pattern standard deviation (dB) (mean ± SD) | 5.92 ± 7.51 |

MLT was completed in all eyes with the laser settings shown in Table 2

| Table 2  Laser Settings |
|-------------|
| Laser wavelength | 577 nm |
| Contact lens    | MLT lens |
| Spot size       | 300 μm |
| Power           | 1000 mW |
| Location of treatment | Pigmented trabecular meshwork |
| Degree of treatment | 360 degree (130 shots) |
| Treatment duration | 300 ms |
| Duty cycle      | 15% duty, 85% rest |
IOP measurement were routinely carried out on day 0, day 1 and in week 1, month 1, month 3, month 6, month 18, and month 36. Anti-glaucoma drugs were titrated up or down when the IOP was higher or lower than the targeted one. When multiple drugs were needed, the combination medications were applied to simplify the drug regimen. If the IOP or optic nerve damage was progressed at maximal drug regimen during more than two visit intervals, the patients received additional therapies, such as another laser treatment or filtering surgery.

Ethical Approval
This study adhered to the tenets of the Declaration of Helsinki. Informed patient consent and approval from the Institutional Review Board of The Second Xiangya Hospital were obtained.

Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics (IBM Corp.) and GraphPad Prism 7 (GraphPad Software, Inc.). Repeated-measures analysis of variance (ANOVA) was used to compare IOP values at different time points with Dunnett’s multiple-comparisons test for between-groups analysis. A Kaplan–Meier analysis was performed to tell the time to failure after MLT. For all statistical analyses performed, differences were considered statistically significant at \( P < 0.05 \).

Results
A total of 39 eyes from 25 patients were enrolled in this study. The patient demographics are shown in Table 1.

No complication occurred during or after MLT. The average follow-up time was 35 ± 1.53 months (range 34.45 to 35.55 months). The mean IOP and number of medications at different time intervals following MLT for all patients were listed in Table 3.

During the follow-up period, seven eyes received additional laser or surgical treatment. These procedures included selective laser trabeculoplasty (SLT) in 4 eyes, shunt implantation in 2 eyes, and trabeculectomy in 1
eye. A survival curve analysis is presented in Fig. 1, in which mortality is defined as the presence of progressive IOP elevation or optic nerve damage, due to which the patients received further laser or surgical treatment.

Only patients without MLT treatment failure, who could be evaluated from the beginning to the end of the 35-month observation period, were analyzed. The Kolmogorov–Smirnov test was performed ($P > 0.05$), which demonstrated that the data was suitable for repeated-measures ANOVA analysis. After 1 day, 3 months, 6 months, and 36 months of MLT, more than 20% patients exhibited a more than 20% IOP reduction, while the mean IOP was significantly reduced at 1 day ($q = 3.12, P = 0.0218, DF = 31$), 3 months ($q = 2.876, P = 0.039, DF = 31$), and 6 months ($q = 2.945, P = 0.0332, DF = 31$) visit compared with the pre-MLT level (Table 4, Fig. 2, $P < 0.05$). On day 1 ($q = 5.23, P = 0.0001, DF = 31$) and in week 1 ($q = 4.836, P = 0.0002, DF = 31$), the number of medications is significantly reduced (Table 4, $P < 0.05$). Besides, at the end of the study, the number of eyes

**Table 4** Changes in IOP and Number of Medications at Different Time Intervals following MLT for Patients without MLT Treatment Failure

|                      | Pre-ML | 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 18 Months | 36 Months |
|----------------------|--------|-------|--------|---------|----------|----------|-----------|-----------|
|                      | $N = 32$ | $N = 32$ | $N = 32$ | $N = 32$ | $N = 32$ | $N = 32$ | $N = 32$ | $N = 32$ |
| IOP (mm Hg ± SD)     | 19.28 ± 4.17 | 17.31 ± 4.72 | 20.55 ± 4.63 | 17.22 ± 4.88 | 17.84 ± 4.31 | 16.97 ± 4.42 | 17.92 ± 4.31 | 18.56 ± 5.66 |
| Range                | (17.78–20.78) | (15.61–19.01) | (18.89–22.22) | (17.46–20.98) | (16.47–19.22) | (15.38–18.56) | (16.37–19.48) | (16.52–20.60) |
| Percent reduction (%)| –      | 10.21  | -6.60  | 0.32    | 7.46     | 12.0     | 7.05      | 3.73      |
| $P$                  | –      | 0.0218 | 0.3130 | 0.9999  | 0.0390   | 0.0332   | 0.0986    | 0.9248    |
| Number of medications| 0.78 ± 0.79 | 0.31 ± 0.47 | 0.25 ± 0.51 | 0.47 ± 0.67 | 0.53 ± 0.62 | 0.59 ± 0.67 | 0.59 ± 0.67 | 0.69 ± 0.64 |
| $P$                  | –      | 0.001 | 0.0002 | 0.1115  | 0.4033   | 0.6642   | 0.7397    | 0.9652    |
| Number of patients with prostaglandin: | 8 | 1 | 1 | 6 | 9 | 12 | 12 | 17 |
| $> 20\%$ IOP reduction (%) | - | 25.0 | 0 | 6.25 | 21.88 | 28.13 | 15.63 | 21.88 |

**Fig. 2** Changes in IOP following MLT with SD bars above and below the Mean. MLT = Micro-Pulse laser trabeculoplasty
needed prostaglandin increased from 8 to 17. However, no significant difference was observed in the number of anti-glaucoma medications between the pre-operative visit and the last visit.

In addition, patients with OHT or OAG could be comparatively analyzed during the observation period, as seen in Table 5 and Fig. 3. After 1 day, 3 months, 6 months, 18 months, and 36 months of MLT, more than 20% patients with OAG exhibited a more than 20% IOP reduction, while more than 20% patients with OHT exhibited a more than 20% IOP reduction after 1 day, 6 months, and 36 months of MLT. The OHT patients had a higher average starting IOP (22.45 mmHg) than the OAG group (17.31 mmHg), approaching significance ($P=0.0009$). After 1 day of MLT, there was no significant difference in IOP between the above groups, while the IOP of OAG patients was significantly lower than the OHT patients at 1 month ($P=0.0124$), 3 months

### Table 5 Changes in IOP at Different Time Intervals following MLT for Patients with OHT or OAG

|                      | Pre-ML | 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 18 Months | 36 Months |
|----------------------|--------|-------|--------|---------|----------|----------|-----------|-----------|
| **OHT (N=11)**       |        |       |        |         |          |          |           |           |
| IOP (mm Hg±SD)       | 22.45±2.62 | 18.27±3.95 | 21.55±4.18 | 20.91±4.00 | 20.36±3.08 | 18.64±4.34 | 20.91±2.59 | 20.36±3.76 |
| Range                | (18.00–26.00) | (13.00–26.00) | (16.00–26.00) | (14.00–24.00) | (11.00–24.00) | (17.00–25.00) | (14.00–27.00) |          |
| ≥ 20% IOP reduction (%) | –       | 36.36 | 0       | 9.09     | 18.18    | 36.36    | 9.09      | 27.27     |
| **OAG (N=13)**       |        |       |        |         |          |          |           |           |
| IOP (mm Hg±SD)       | 17.31±3.73 | 15.92±4.27 | 19.59±3.70 | 16.58±3.61 | 15.15±3.08 | 15.77±4.97 | 15.81±5.04 | 15.77±4.34 |
| Range                | (9.00–21.00) | (5.00–20.00) | (15.00–27.00) | (10.00–22.00) | (10.00–19.00) | (11.00–28.00) | (11.00–28.00) | (11.00–28.00) |
| ≥ 20% IOP reduction (%) | –       | 23.08 | 0       | 7.69     | 38.46    | 38.46    | 30.77     | 30.77     |
| **P**                | 0.0009 | 0.1787 | 0.2373 | 0.0124  | 0.0004   | 0.1502   | 0.0061    | 0.0119    |

### Table 6 Changes in Number of Medications at Different Time Intervals following MLT for Patients with OHT or OAG

|                      | Pre-ML | 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 18 Months | 36 Months |
|----------------------|--------|-------|--------|---------|----------|----------|-----------|-----------|
| **OHT (N=11)**       |        |       |        |         |          |          |           |           |
| Mean number of medication±SD | 0.36±0.50 | 0.18±0.40 | 0.18±0.40 | 0.36±0.50 | 0.36±0.50 | 0.55±0.52 | 0.55±0.52 |          |
| **OAG (N=13)**       |        |       |        |         |          |          |           |           |
| Mean number of medication±SD | 0.54±0.52 | 0.23±0.44 | 0.15±0.38 | 0.54±0.78 | 0.77±0.733 | 0.84±0.69 | 0.58±0.51 | 0.69±0.48 |
| **P**                | 0.4139 | 0.7804 | 0.8623 | 0.5287  | 0.1329   | 0.0673   | 0.8627    | 0.4808    |
(P=0.0004), 18 months (P=0.0061) and 36 months (P=0.0119). Moreover, the number of medications between groups showed no significant difference at follow-up intervals (Table 6).

Discussion
As universally acknowledged, argon laser trabeculoplasty (ALT) exerts thermal damage to the treated TM, causing the shrinkage of collagen fibres, stretching and widening the adjacent areas and allow more outflow [11]. Compared to ALT, SLT’s energy selectively absorbed by pigmented trabecular cells and makes no damage to adjacent structures. Both ALT and SLT provided reliable IOP-lowering effect, but ALT caused obvious damage to TM histologically [11, 12]. Several clinical trials claimed that SLT was an effective way to control IOP in multiple types of glaucoma [13–17]. However, a wide range of complications, such as redness, photophobia, peripheral anterior synechiae, and cystoid macular oedema were still observed in patients with SLT [18].

Unlike the former laser technologies, MLT is based on a micropulse laser with a 15% duty cycle, which allows the temperature to return to the baseline. Under this condition, both TM and Schlemm’s canal could escape from cellular damage, scarring, and morphological changes [19].

Previous research demonstrated that MLT (810 nm) was less effective in reducing IOP compared with ALT on a 3-month visit [20]. A retrospective review was conducted by Rantala, in which they evaluated 180° MLT (810 nm, 180°) on patients with OAG with a minimum follow-up period of 6 months, and found that MLT was a safe but not effective-enough treatment for glaucoma [4]. Lee investigated the use of 360° MLT (577 nm) for treating patients with OAG. By the end of the 6-month visit, 72.9% of patients were successfully treated [5]. Abramowitz carried out a prospective randomized clinical trial, comparing 360° MLT (577 nm) with 360° SLT. He showed that MLT was as effective as SLT within a 52-week follow-up period [21]. Valera-Cornejo conducted MLT (532 nm, 360°) on patients with OAG and found that it reduced IOP in a pretty short period [6]. All of the above indicated that both the range and the wavelength of laser applied to patients may affect the results. In the present study, IOP was averagely reduced by 3.73%, and only 21.88% of the patients achieved a more 20% reduction in IOP by the end of the 35-month visit, despite adding a topical therapy of prostaglandins to 9 more eyes (from 8 to 17). Furthermore, compared with the OHT group, the IOP-reducing effect of MLT was more pronounced in the OAG group. This result was not as encouraging as the previous findings. Recently, several studies claimed that MLT is a safe and effective way to attenuate IOP, while the observation period was relatively short [8, 22–24].

The present study had several limitations. Initially, this was a small-sample study. Patients’ characterizations, such as the optic nerve condition, might have affected the results. Seven eyes with a C/D ratio range from 0.9 to 1.0 were enrolled, four of them underwent trabeculectomy, demonstrating a poor prognosis. The reason why we recruit them is because several anti-glaucoma drugs had been prescribed but not sufficient to lower the IOP in these patients. To reduce the glaucoma medications and slow down the progression of optic nerve damage, we decided to perform MLT to these 4 eyes. Secondly, given the relatively long follow-up period, it was hard for patients to completely following doctors’ instructions. Especially, those who still have a relatively good visual acuity, might not apply drugs as routinely as required, leading to an underestimated IOP-lowering effect. Lastly, this inhomogeneous cohort whose patients enrolled suffered from many different types of glaucoma might have influenced the results enormously.

To our knowledge, this research was one of the longest explorations of the effect of MLT on patients with glaucoma and OHT, claiming that a single session of MLT could significantly reduce IOP in a pretty short period. Given the repeatability of MLT, it could be used as an IOP-lowering treatment.

Conclusion
MLT is a newly glaucoma treatment based on a micropulse laser with a 15% duty cycle, which could reduce IOP in patients with glaucoma or ocular hypertension for a short period, but its lowering efficiency was limited up to 6 months of the follow-up period.

Abbreviations
ANOVA: Repeated-measures analysis of variance; BCVA: Best-corrected visual acuity; C/D ratio: Vertical cup-to-disc ratio; IOP: Intraocular pressure; LTP: Laser trabeculoplasty; MLT: Micropulse laser trabecular plasty; OH: Ocular hypertension; RNFL: Retinal nerve fibre layer; SLT: Selective laser trabeculoplasty; TM: Trabecular meshwork; VF: Visual field.

Acknowledgements
The authors thank their colleagues from the Department of Ophthalmology at the Second Xiangya Hospital who provided their insights and expertise during the research.

Authors’ contributions
Yuting Yang and Xinting Huang analyzed the data and wrote this paper, Sheng Liao and Feng Zhang collected the data, Jingming Shi provided clinical consultation to the patients involved, Ke Liu and Xuanchu Duan revised and polished this paper. All authors read and approved the final manuscript.

Funding
This study was supported financially by the Science Foundation from the Bureau of Science and Technology of Changsha City. (No. kq1701094) and
the Fundamental Research Funds for the Central Universities of Central South University (Nos.2021zzts1067).

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study adhered to the tenets of the Declaration of Helsinki. Informed patient consent and approval from the Institutional Review Board of The Second Xiangya Hospital were obtained.

Consent for publication
Not applicable.

Competing interests
There is no conflict of interest to declare.

Author details
1 Department of Ophthalmology, Second Xiangya Hospital, Central South University, Hunan 410011, China. 2 Department of Ophthalmology & Visual Science, ENT Hospital, Shanghai Medical College, Fudan University, Eye & Shanghai 200031, China. 3 Department of Ophthalmology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China. 4 Changsha Aier Eye Hospital, Changsha, Hunan, China.

Received: 30 August 2021   Accepted: 26 May 2022

Published online: 04 June 2022

References
1. Jonas J, Aung T, Bourne R, Bron A, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017;390(10108):2183–93.
2. Kumar H, Mansoori T, Warjri G, Somarajan B, Bandil S, Gupta V. Lasers in glaucoma. Indian J Ophthalmol. 2018;66(1):1539–53.
3. Tsang S, Cheng J, Lee J. Developments in laser trabeculoplasty. Br J Ophthalmol. 2016;100(1):94–7.
4. Rantala E, Valimäki J. Micropulse diode laser trabeculoplasty – 180-degree treatment. J Acta Ophthalmologica. 2012;90(5):441–4.
5. Lee J, Yau G, Yick D, Yuen C. Micropulse laser for the treatment of open-angle glaucoma. Medicine (Baltimore). 2015;94(49): e2075.
6. Valera-Cornejo DA, Loayza-Gamboa W, Herrera-Quiroz J, Alvarado-Villacorta R, Cordova-Crisanto I, Valdemar-Albino V, Davalos NP. Micropulse trabeculoplasty in open angle glaucoma. Adv Biomed Res. 2018;7:156.
7. Makri OE, Pallikari A, Pagoulatos D, Kagkelaris K, Plotas P, Georgakopoulos CD. Effect of intraocular pressure in the first 24 hours after micropulse laser trabeculoplasty in eyes with pseudoxfoliation glaucoma. J Fr Ophthalmol. 2019;42(9):983–6.
8. Hong Y, Song SJ, Liu B, Hassanpour K, Zhang C, Loewen N. Efficacy and safety of micropulse laser trabeculoplasty for primary open angle glaucoma. Int J Ophthalmol. 2019;12(5):784–8.
9. Hirabayashi MT, Rosenlof TL, An JA. Comparison of successful outcome predictors for MicroPulse(R) laser trabeculoplasty and selective laser trabeculoplasty at 6 months. Clin Ophthalmol. 2019;13:1001–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more: biomedcentral.com/submissions